Metastatic Liver Cancer - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 146

Metastatic Liver Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Metastatic Liver Cancer - Pipeline Review, H2 2012', provides an overview of the Metastatic Liver Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer. 'Metastatic Liver Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Liver Cancer.
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Liver Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Metastatic Liver Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Liver Cancer Therapeutic Products under Development, Key Players in Metastatic Liver Cancer Therapeutics, Metastatic Liver Cancer Pipeline Overview, Metastatic Liver Cancer Pipeline, Metastatic Liver Cancer Pipeline Assessment

2
List of Tables 4
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Metastatic Liver Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Metastatic Liver Cancer 9
Metastatic Liver Cancer Therapeutics under Development by Companies 11
Metastatic Liver Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Metastatic Liver Cancer Therapeutics – Products under Development by Companies 21
Metastatic Liver Cancer Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Metastatic Liver Cancer Therapeutics Development 24
F. Hoffmann-La Roche Ltd. 24
Tekmira Pharmaceuticals Corp. 25
Delcath Systems, Inc. 26
Chugai Pharmaceutical Co. Ltd 27
Aduro BioTech 28
Provectus Pharmaceuticals, Inc. 29
Transgene Biotek Ltd 30
RXi Pharmaceuticals Corporation 31
Metastatic Liver Cancer – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
RG7686 - Drug Profile 38
Provecta - Drug Profile 39
Cisplatin + Liposomal Doxorubicin - Drug Profile 41
Cetuximab + Dasatinib - Drug Profile 42
Sorafenib + Radiation therapy - Drug Profile 44
Cetuximab + Irinotecan + Oxaliplatin + 5-Fluorouracil - Drug Profile 45
Oxaliplatin - Drug Profile 46
Sorafenib - Drug Profile 47
Irinotecan + Bevacizumab - Drug Profile 49
Isolated Perfusion + Melphalan - Drug Profile 50
Salmonella Typhimurium - Drug Profile 52
Melphalan + Chemosaturation Therapy - Drug Profile 53
rRp450 - Drug Profile 55
GC33 + Nexavar - Drug Profile 56
CPT-11 + 5-Fluorouracil + Leucovorin - Drug Profile 57
Tarceva + Avastin - Drug Profile 58
Avastin + Tarceva - Drug Profile 59
Cetuximab - Drug Profile 60
Dasatinib - Drug Profile 61
Fluorouracil + Leucovorin - Drug Profile 62
Fluorouracil + Leucovorin Calcium 1 - Drug Profile 63
Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66 + Floxuridine + Gemcitabine - Drug Profile 64
Eicosapentaenoic Acid - Drug Profile 65
CEA-Loaded Dendritic Cell Vaccine - Drug Profile 66
FOLFOX4 - Drug Profile 67
Floxuridine + Oxaliplatin + Capecitabine - Drug Profile 68
Floxuridine + Fluorouracil + Leucovorin - Drug Profile 70
Oxaliplatin + Fluorouracil + Leucovorin Calcium - Drug Profile 71
Oxaliplatin + Fluorouracil + Leucovorin Calcium + Cetuximab - Drug Profile 73
Oxaliplatin + Capecitabine - Drug Profile 75
FOLFOX6 + Cetuximab - Drug Profile 77
Cetuximab + Irinotecan + Oxaliplatin + 5-Fluorouracil - Drug Profile 79
Cetuximab + FOLFIRI - Drug Profile 81
Doxorubicin + Sorafenib - Drug Profile 83
Cisplatin + Doxorubicin + Mitomycin C - Drug Profile 85
Bevacizumab + Capecitabine + Oxaliplatin - Drug Profile 87
Cediranib Maleate - Drug Profile 88
Capecitabine + Oxaliplatin - Drug Profile 89
Lyso-Thermosensitive Liposome Doxorubicin - Drug Profile 90
XELOX + MoAb - Drug Profile 91
FOLFOX - Drug Profile 92
Bevacizumab + XELOX - Drug Profile 94
TKM-PLK1 - Drug Profile 96
Leucovorin + Tegafur + Uracil - Drug Profile 98
Oxaliplatin + 5-Fluorouracil + Bevacizumab - Drug Profile 99
Oxaliplatin + Bevacizumab - Drug Profile 101
Oxaliplatin + Bevacizumab + Leucovorin + 5-Fluorouracil - Drug Profile 102
Oxaliplatin + Cetuximab + Bevacizumab - Drug Profile 104
Oxaliplatin + 5-Fluorouracil + Leucovorin - Drug Profile 106
Irinotecan + Bevacizumab + Cetuximab - Drug Profile 107
Floxuridine + Gemcitabine Hydrochloride - Drug Profile 108
Gemcitabine + Oxaliplatin + Nexavar - Drug Profile 110
Allogeneic Tumor Cell Vaccine + Iscomatrix + Celecoxib + Cyclophosphamide - Drug Profile 112
mFOLFOX6 + Cetuximab - Drug Profile 114
Theracim + 5-FU + Lipidol - Drug Profile 116
Oxaliplatin + Floxuridine + Leucovorin - Drug Profile 117
Panitumumab + FOLFOX - Drug Profile 118
Oncology Program - Drug Profile 120
FOLFOXIRI + Panitumumab - Drug Profile 121
Enoxaparin + Pentoxifylline + Ursodeoxycholic Acid - Drug Profile 123
ANZ-100 - Drug Profile 125
TBL-0404 - Drug Profile 126
FOLFOXIRI + Bevacizumab - Drug Profile 127
Metastatic Liver Cancer Therapeutics – Drug Profile Updates 129
Metastatic Liver Cancer Therapeutics – Discontinued Products 135
Metastatic Liver Cancer Therapeutics - Dormant Products 136
Metastatic Liver Cancer – Product Development Milestones 137
Featured News & Press Releases 137
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 142
Disclaimer 142

List of Tables
Number of Products Under Development for Metastatic Liver Cancer, H2 2012 13
Products under Development for Metastatic Liver Cancer – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 26
F. Hoffmann-La Roche Ltd., H2 2012 28
Tekmira Pharmaceuticals Corp., H2 2012 29
Delcath Systems, Inc., H2 2012 30
Chugai Pharmaceutical Co. Ltd, H2 2012 31
Aduro BioTech, H2 2012 32
Provectus Pharmaceuticals, Inc., H2 2012 33
Transgene Biotek Ltd, H2 2012 34
RXi Pharmaceuticals Corporation, H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Metastatic Liver Cancer Therapeutics – Drug Profile Updates 133
Metastatic Liver Cancer Therapeutics – Discontinued Products 139
Metastatic Liver Cancer Therapeutics – Dormant Products 140

List of Figures
Number of Products under Development for Metastatic Liver Cancer, H2 2012 13
Products under Development for Metastatic Liver Cancer – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41

Customers who bought this item also bought

• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012
• Adenocarcinoma - Pipeline Review, H2 2012
• Metastatic Prostate Cancer - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012